Literature DB >> 2331581

Vascular effects of helodermin, helospectin I and helospectin II: a comparison with vasoactive intestinal peptide (VIP).

L Grundemar1, E D Högestätt.   

Abstract

1. Helodermin, helospectin I and helospectin II, peptides recently isolated from the salivary gland venom of Heloderma suspectum, were compared to vasoactive intestinal peptide (VIP) with respect to effects on systemic blood pressure and on isolated femoral arteries in the rat. 2. They all reduced blood pressure in a dose-dependent manner; helodermin was less effective than VIP. However, at doses higher than 1 nmol kg-1 all four peptides reduced blood pressure to about the same extent. 3. The half-life of the hypotensive effect of VIP was longer than that of helodermin and the helospectins. 4. VIP and helodermin were equally potent in relaxing femoral arteries precontracted with phenylephrine or prostaglandin F2 alpha. 5. Helospectin I and II relaxed phenylephrine-contracted vessels to the same extent as VIP but with a lower potency. 6. Addition of VIP 1 microM to preparations exposed to helodermin 1 microM or to either of the helospectins did not produce a further relaxation. 7. The findings indicate that VIP, helodermin and helospectin I and II have a similar profile of action and therefore may act on a common receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331581      PMCID: PMC1917339          DOI: 10.1111/j.1476-5381.1990.tb12962.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Helodermin-like peptides in noradrenaline cells of adrenal medulla.

Authors:  A Bjartell; P Persson; A Absood; F Sundler; R Håkanson
Journal:  Regul Pept       Date:  1989-08

2.  Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom.

Authors:  M Hoshino; C Yanaihara; Y M Hong; S Kishida; Y Katsumaru; A Vandermeers; M C Vandermeers-Piret; P Robberecht; J Christophe; N Yanaihara
Journal:  FEBS Lett       Date:  1984-12-10       Impact factor: 4.124

3.  Specific labelling by [125I]helodermin of high-affinity VIP receptors in rat liver membranes.

Authors:  P Robberecht; M Waelbroeck; P de Neef; J C Camus; A Vandermeers; M C Vandermeers-Piret; J Christophe
Journal:  FEBS Lett       Date:  1984-06-25       Impact factor: 4.124

4.  Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels.

Authors:  E D Högestätt; K E Andersson; L Edvinsson
Journal:  Acta Physiol Scand       Date:  1983-01

5.  Helodermin has a VIP-like effect upon canine blood flow.

Authors:  S Naruse; A Yasui; S Kishida; M Kadowaki; M Hoshino; T Ozaki; P Robberecht; J Christophe; C Yanaihara; N Yanaihara
Journal:  Peptides       Date:  1986       Impact factor: 3.750

6.  Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom.

Authors:  A Vandermeers; M C Vandermeers-Piret; P Robberecht; M Waelbroeck; J P Dehaye; J Winand; J Christophe
Journal:  FEBS Lett       Date:  1984-01-30       Impact factor: 4.124

7.  Comparison of helodermin, VIP and PHI in pancreatic secretion and blood flow in dogs.

Authors:  S J Konturek; N Yanaihara; W Pawlik; J Jaworek; K Szewczyk
Journal:  Regul Pept       Date:  1989-02

8.  Is helodermin produced by medullary thyroid carcinoma cells and normal C-cells? Immunocytochemical evidence.

Authors:  F Sundler; J Christophe; P Robberecht; N Yanaihara; C Yanaihara; T Grunditz; R Håkanson
Journal:  Regul Pept       Date:  1988-01

9.  Helodermin-like peptides in thyroid C cells: stimulation of thyroid hormone secretion and suppression of calcium incorporation into bone.

Authors:  T Grunditz; P Persson; R Håkanson; A Absood; G Böttcher; C Rerup; F Sundler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

10.  Amino acid sequences of helospectins, new members of the glucagon superfamily, found in Gila monster venom.

Authors:  D S Parker; J P Raufman; T L O'Donohue; M Bledsoe; H Yoshida; J J Pisano
Journal:  J Biol Chem       Date:  1984-10-10       Impact factor: 5.157

  10 in total
  6 in total

1.  Distribution and co-localization of immunoreactive helospectin with vasoactive intestinal polypeptide and peptide histidine methionine in human nasal mucosa, soft palate and larynx.

Authors:  C E Hauser-Kronberger; G W Hacker; F Sundler; J Thurner; K Albegger
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

2.  Effects of helospectin I on insulin and glucagon secretion in the mouse.

Authors:  B Ahrén
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.

Authors:  P Hedlund; P Alm; P Ekström; J Fahrenkrug; J Hannibal; H Hedlund; B Larsson; K E Andersson
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

4.  Distribution of PACAP (pituitary adenylate cyclase-activating polypeptide)-like and helospectin-like peptides in the teleost gut.

Authors:  C Olsson; S Holmgren
Journal:  Cell Tissue Res       Date:  1994-09       Impact factor: 5.249

5.  Enter the Dragon: The Dynamic and Multifunctional Evolution of Anguimorpha Lizard Venoms.

Authors:  Ivan Koludarov; Timothy Nw Jackson; Bianca Op den Brouw; James Dobson; Daniel Dashevsky; Kevin Arbuckle; Christofer J Clemente; Edward J Stockdale; Chip Cochran; Jordan Debono; Carson Stephens; Nadya Panagides; Bin Li; Mary-Louise Roy Manchadi; Aude Violette; Rudy Fourmy; Iwan Hendrikx; Amanda Nouwens; Judith Clements; Paolo Martelli; Hang Fai Kwok; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2017-08-06       Impact factor: 4.546

6.  Varanid Lizard Venoms Disrupt the Clotting Ability of Human Fibrinogen through Destructive Cleavage.

Authors:  James S Dobson; Christina N Zdenek; Chris Hay; Aude Violette; Rudy Fourmy; Chip Cochran; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2019-05-07       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.